alendronate / Generic mfg. - LARVOL DELTA

A Systematic Review of the Effects of Bisphosphonates on Osteoblasts In Vitro. (PubMed, Calcif Tissue Int) - "Additionally, studies have shown that certain BPs, such as zoledronic acid, can interfere with osteoblast differentiation, proliferation, gene expression, and mineralization capacity, potentially impairing bone healing. On the other hand, other drugs, such as alendronate, demonstrate more positive effects on cell function. Some drugs, such as pamidronate and clodronate, exhibited mixed effects; however, it was observed that high concentrations of these drugs can lead to cytotoxic effects. Despite these adverse effects, it is important to recognize that the clinical benefits of managing bone disorders often outweigh the potential risks highlighted in this review."

Journal • Preclinical • Review • Oncology • Orthopedics • Solid Tumor

Targeted expansion of cytotoxic T cells using IL-12 and CD137L supplementation enhances antitumor efficacy. (PubMed, Mol Ther Oncol) - "Here, we show the in vitro expansion of cytotoxic Vδ2 T cells expressing CD16 and NKG2A enriched in granzyme B that displayed enhanced antitumor activity of up to 40% against leukemia and ovarian, breast, and lung cancer cells. Our work warrants clinical testing to evaluate the therapeutic potential of these highly cytotoxic cells, paving the way for improved efficacy of personalized cell-based immunotherapies."

Journal • Breast Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Oncology • Solid Tumor • GZMB • IL12A • KLRC1

ANTIRESORPTIVE TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: DO ORALLY ADMINISTERED DRUGS WORK (EULAR 2025) - "Antiresorptive therapies included alendronate (n=17), zoledronate (n=7), denosumab (n=11), risedronate (n=2), and ibandronate (n=1). Antiresorptive therapy appears effective and safe in patients with SSc. Subgroup analysis suggests that parenteral therapies may be more effective, with denosumab showing the most consistent improvements in axial BMD. Notably, both oral and parenteral antiresorptive drugs were well-tolerated, as no adverse events were observed."

Clinical • Gastrointestinal Disorder • Immunology • Osteoporosis • Rheumatology • Scleroderma • Systemic Sclerosis

MULTI-TARGET THERAPY IN PREVENTION OF STEROID-INDUCED OSTEONECROSIS: A RANDOMIZED CONTROLLED CLINICAL TRIAL. PRELIMINARY REPORT (EULAR 2025) - "The intervention group was administered a daily dosage of atorvastatin (40 mg), Aspirin (80 mg), and vitamin E (400 mg), along with a weekly dose of alendronate (70 mg). The initial findings suggest that a multi-target therapy could potentially prove effective in both preventing and mitigating steroid-induced osteonecrosis. While the multi-target therapy demonstrated a trend toward reducing the incidence of steroid-induced osteonecrosis, this observation did not reach statistical significance."

Clinical • Metabolic Disorders

ANALYSIS OF BONE TURNOVER MARKERS IN PATIENTS TREATED WITH ROMOSOZUMAB IN CLINICAL PRACTICE (EULAR 2025) - "Regarding prior treatment, 8 patients had received bisphosphonates (BF) (4 zoledronate, 4 alendronate), 4 teriparatide, 3 denosumab (Dmab), and 2 raloxifene. In real-world clinical practice, the prior therapeutic sequence influences both BTM and BMD responses to Rmab. Patients previously treated with BF achieved superior BMD increases compared to those transitioning from teriparatide or Dmab. The BTM behavior suggests a potential “rebound” effect in patients transitioning from Dmab to Rmab."

Clinical • Musculoskeletal Diseases • Orthopedics • Otorhinolaryngology • Respiratory Diseases • Sinusitis

ROMOSOZUMAB IN PATIENTS WITH OSTEOPOROSIS: SAFETY AND EFFICACY ANALYSIS IN CLINICAL PRACTICE (EULAR 2025) - "Following romosozumab, the most frequently used therapies were denosumab (44.4%), risedronate (27.8%), zoledronic acid (13.9%), alendronate (5.6%), and teriparatide (2.8%). Romosozumab therapy represents a safe bone-forming treatment option for elderly patients with established classic cardiovascular risk factors. An increase in bone formation markers and a reduction in bone resorption markers were observed in blood tests, along with an improvement in bone mineral density as measured by densitometry. The most commonly used treatment following romosozumab was denosumab, followed by bisphosphonates."

Clinical • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Non-melanoma Skin Cancer • Osteoporosis • Pain • Parotid Gland Cancer • Rheumatology • Skin Cancer • Solid Tumor

SUBTROCHANTERIC FEMORAL FRACTURES (ATYPICAL OR NOT) AND PREVIOUS TREATMENT WITH BISPHOSPHONATE (EULAR 2025) - "In patients with subtrochanteric fracture, 6 had received alendronate, 1 risedronate and 1 denosumab. Subtrocanteric femoral fractures are associated with higher BMI and the use of bisphosphonate or denosumab. Atypical fracture is rare, accounting only 3% of subtrocanteric type."

Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "A total of 36 (16.7%) patients were exposed to bisphosphonate therapy including Alendronate(17), Ibandronate(4), Risedronate(6), Zoledronate(9), and 13, 3, 4, and 8 patients were detected with low BMD, respectively. This is the first study evaluating the prevalence of low BMD in young patients with SLE in India. Low BMD was observed in 28.12% of patients. In SLE, nephritis and higher cumulative dose of glucocorticoids may contribute to elevated fracture risk."

Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Rheumatology • Systemic Lupus Erythematosus

Teriparatide in the real world - efficacy and safety (EULAR 2025) - "Alendronate was the most common first-line bisphosphonate...After Teriparatide, 40 patients (74%) transitioned to Denosumab, 7 (13%) began Zoledronic acid, 5 passed away, and 2 were lost to follow-up... Our study demonstrates real world use of Teriparatide in a multi-ethnic diverse setting. It shows that Teriparatide is used predominantly in complex, multi-morbid older individuals with several prior fractures. Despite that, Teriparatide remains effective for a wide range of individuals including those with inflammatory arthritis and/or concurrent steroid use."

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Paget's Disease of Bone: Clinical and Epidemiological Profiling of a Portuguese Cohort at a Tertiary Center (EULAR 2025) - "First line treatment was with zoledronate in 60 (75.0%) patients, pamidronate in 8 (10.0%) patients, alendronate in 4 (5.0%) patients, calcitonin in 3 (3.8%) patients, risedronate in 1 (1.3%) patient and denosumab in 1 (1.3%) patient. To the best of our knowledge, this study describes the largest Portuguese cohort of PDB patients. A high prevalence of this disease in rural areas and a high biochemical remission rate after treatment were noted. Patients treated with a non-zoledronate drug as first line therapy had a higher rate of retreatment than patients treated with zoledronate as first line therapy (HR 10.10)."

Clinical • Orthopedics • Rare Diseases

RATES OF CONCURRENT BMD RESPONSES AT THE LUMBAR SPINE AND TOTAL HIP IN PATIENTS RECEIVING ROMOSOZUMAB OR TERIPARATIDE FOLLOWING BISPHOSPHONATE THERAPY: A POST HOC ANALYSIS OF THE RANDOMISED PHASE 3 STRUCTURE TRIAL (EULAR 2025) - P3 | " In STRUCTURE, postmenopausal women with osteoporosis who had received an oral BP for ≥3 years (mean [SD] duration: 6.2 [2.9] years) and alendronate for the year prior to screening were randomised to subcutaneous Romo 210 mg monthly (QM) or TPTD 20 µg daily for 12 months [3]. A substantially greater proportion of previously BP-treated postmenopausal women receiving Romo had >3%/>6% concurrent improvements in BMD at both the LS and TH within 12 months compared with TPTD. These data add to the evidence indicating superiority of Romo in attaining BMD improvements within 12 months, across key skeletal sites in patients with osteoporosis."

Clinical • P3 data • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Buffered soluble alendronate treatment preventing rebound following denosumab discontinuation in erosive hand OA: a randomized trial (EULAR 2025) - "A 48-week buffered soluble alendronate regimen more effectively prevents bone loss following denosumab withdrawal in erosive HOA patients compared to a 24-week regimen, supporting a safe denosumab discontinuation protocol. Exploratory outcomes suggest alendronate does not arrest radiographic progression nor deterioration of hand pain."

Clinical • Immunology • Osteoarthritis • Osteoporosis • Pain • Rheumatology

Enhancement of implant performance through synergistic drug delivery and bioactivity by nanotubular titanium with hydroxyapatite coating. (PubMed, Int J Pharm) - "The in vitro drug release evaluated using the alendronate and gentamicin shows sustained release with the release of 92 % and 94 %, respectively. The bioactivity by in vitro immersion studies indicated that this bioimplant promoted apatite formation, suggesting enhanced bone-bonding potential. These results suggest the potential of the drug elucidating implant surfaces as an application towards dental and orthopedic implants."

Journal • Infectious Disease • Orthopedics

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study. (PubMed, Cureus) - "Several drugs were disproportionately associated with CTS in the FAERS database, including enzyme replacement therapies (ERTs), aromatase inhibitors, bisphosphonates, growth hormone (GH)-releasing factor analogs, GHB, rofecoxib, and tafamidis. These findings highlight the critical need for increased vigilance and monitoring of new-onset or worsening CTS in high-risk populations prescribed the aforementioned medications. Clinicians should carefully scrutinize pharmacological history when evaluating patients in this context."

Adverse events • Journal • Musculoskeletal Pain • Pain

Multifunctional enzymatically crosslinked hyaluronic acid/gelatin/mesoporous bioactive glass nanocomposite hydrogel as an alendronate carrier for treating osteoporotic fractures. (PubMed, Int J Biol Macromol) - "Incorporating ALN into HGB-0.5 % hydrogels also decreased the differentiation of RAW 264.7 cells into osteoclasts. These results highlight the potential of ALN-loaded HGB-0.5 % hydrogels with osteo-induction, osteo-conduction, and anti-osteoclastogenesis properties for treating osteoporotic fractures."

Journal • Musculoskeletal Diseases • Orthopedics

Preparation of titanium (IV)-immobilized covalent organic polymer and use for simultaneous enrichment of nucleotides and catecholamines at weakly acidic pH. (PubMed, J Chromatogr A) - "In this study, a titanium (IV)-immobilized affinity adsorbent, TpBD-(COOH)2@AS@Ti4+, was prepared by functionalizing hydroxyl bearing covalent organic polymer (COP) with alendronate, and the adsorbent was used for simultaneous enrichment of CAs and NTs under weakly acidic conditions (pH 6.0), which can prevent the oxidation of CAs and improve the accuracy of their analysis...Meanwhile, CAs achieved higher sensitivity with LODs of 0.24-0.79 ng/mL when using the FL detector. Therefore, this study has important application potential for providing more comprehensive clinical diagnostic information and early diagnosis of diseases."

Journal • Inflammatory Arthritis

Prolonged hypercalcemia induced by teriparatide: a case report and literature review. (PubMed, Osteoporos Int) - "After failing treatment with etidronate, alendronate, and denosumab in view of minimal improvement in bone density and multiple fragility fractures, she was started on teriparatide on 5 May 2023. Teriparatide was discontinued since 27 September 2023 and normalization of serum calcium was noted on 31 October 2023.The cumulative effect of teriparatide from relative "overdosing" may be a contributing factor for prolonged hypercalcemia in our case, given she had a body mass index of 14.42 kg/m2 but received the standard dose of 20 mcg teriparatide subcutaneously daily. This case underscores the necessity for vigilance in monitoring patients at risk of hypercalcemia during teriparatide therapy. Furthermore, it prompts further investigation into personalized dosing strategies, i.e., in underweight patients."

Journal • Endocrine Disorders • Immunology • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatoid Arthritis • Rheumatology

Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate. (PubMed, Front Endocrinol (Lausanne)) - P=N/A | "Age and menopausal status considerations are critical for optimizing denosumab therapy in OI. https://www.chictr.org.cn/bin/project/edit?pid=184231, identifier ChiCTR2300074207."

Journal • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Pediatrics

Research on the regulatory mechanism of bone metabolism in the central nervous system (ChiCTR) - P=N/A | N=90 | Completed | Sponsor: Shenzhen Bao'an Chinese Medicine Hospital; Shenzhen Bao'an Chinese Medicine Hospital

New trial • Osteoporosis • Rheumatology

Iodine-Induced Thyrotoxicosis Leading to Severe Osteoporosis: A Case Report (ENDO 2025) - "Common sources include iodized salt, amiodarone, and seaweed-based supplements such as kelp. We report a case of iodine-induced thyrotoxicosis secondary to kelp consumption, resulting in severe osteoporosis, emphasizing the importance of dietary awareness in thyroid management.CaseA 58-year-old woman with osteoporosis, low BMI, and premature ovarian insufficiency (POI) was evaluated for worsening bone density despite prior treatment with alendronate...She was advised to avoid excessive iodine and was treated with prednisone. She also started denosumab but was lost to follow-up...Kelp and similar supplements can exceed the recommended iodine intake of 1,100 mcg/day, necessitating dietary education.This case highlights the difficulty of managing iodine-induced thyrotoxicosis, especially when unrecognized supplement intake is involved. Comprehensive care should include dietary counseling and, when needed, psychiatric evaluation to address behavioral patterns contributing to..."

Case report • Clinical • Cardiovascular • Endocrine Disorders • Movement Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psychiatry • Rheumatology • Women's Health

"Strengthening Bones, Supporting Lives: Romosozumab in Osteoporosis Management for Marfan Syndrome" (ENDO 2025) - "For osteoporosis, patient was previously on alendronate followed by raloxifene with a combined treatment course of approximately 15 years. Given the severity of her osteoporosis, our patient completed a 12-month course of therapy without any significant side effects and was found to have clinically significant improvement in her axial bone mineral density.CONCLUSIONTo our knowledge, there are no case reports on use of Romosozumab in the MFS population with osteoporosis. This case report highlights this therapy as a possible effective therapeutic intervention but also recognizes the need for ongoing research to establish standard and effective treatment guidelines for management of osteoporosis in MFS."

Endocrine Disorders • Genetic Disorders • Grave’s Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • FBN1

A Rare Case of Nail Patella Syndrome and Osteoporosis (ENDO 2025) - "Alendronate was prescribed from 2005 to 2012...Her labs upon consultation in 2024 were notable for serum calcium 9.39 mg/dL (8.6-10.3 mg/dL), 25 hydroxy vitamin D level 70 ng/mL (30-100 ng/mL), and C-telopeptide level 112 pg/mL. Due to her low C-telopeptide and improvement in her DXA a bisphosphonate holiday was reinitiated in 2024.Clinical lessons: Patients with nail patella syndrome have a higher risk of early osteoporosis and should be monitored closely to evaluate for early intervention."

Clinical • Allergic Rhinitis • Dermatology • Endocrine Disorders • Gastroesophageal Reflux Disease • Immunology • Inflammation • Musculoskeletal Diseases • Ophthalmology • Orthopedics • Osteoporosis • Pulmonary Disease • Renal Disease • Rheumatology • Urology

Comparative Effects of Denosumab and Alendronate on Incidence of Type 2 Diabetes Mellitus in Patients with Osteoporosis: A Nationwide Study (ENDO 2025) - "These results suggest that both medications have comparable effects on T2D risk in osteoporosis patients. Given the observational nature of the study and potential residual confounding factors, further prospective research with longer follow-up and detailed clinical data is warranted to clarify the long-term metabolic effects of antiosteoporotic agents."

Clinical • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

Optimal Timing of Denosumab with Parathyroidectomy in the Setting of Primary Hyperparathyroidism​ (ENDO 2025) - "She had difficulty controlling her symptoms with steroid-sparing agents, needing 20-60mg of daily prednisone for 2 years. She started alendronate, calcium citrate, and high dose ergocalciferol prior to presenting to endocrinology... Parathyroidectomy was scheduled in proximity to the next denosumab dose since timing is important due to rebound resorption phenomenon and increased risk of vertebral fractures after delayed or missed denosumab doses. However, peri-procedural hypoparathyroidism and severe hypocalcemia can result if potent anti-resorptive therapy prevents liberation of calcium from bone. Considering this, denosumab was given 8 weeks after parathyroidectomy."

Cardiovascular • Dermatology • Endocrine Disorders • Grave’s Disease • Hypoparathyroidism • Immunology • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psoriasis • Rheumatology • Secondary Hyperparathyroidism

Delayed Diagnosis of Hypophosphatasia in a 91-year-old: An Opportunity to Improve Screening (ENDO 2025) - "His low BMD had been treated with six 5-mg doses of zoledronate (ZOL) from 2010 to 2023 and alendronate prior to 2010...Additional ZOL was held and he was evaluated for asfotase alfa... HPP may be overlooked particularly in older adults with low BMD and low ALP on long-term bisphosphonate therapy as illustrated in this case. Our patient's low ALP level was presumed secondary to longstanding suppression of bone turnover from many years of bisphosphonate exposure. Although bisphosphonates can increase risk of atypical femur fractures in HPP, our patient had no such complications."

CNS Disorders • Depression • Musculoskeletal Diseases • Orthopedics • Otorhinolaryngology • Psychiatry • Rheumatology • ALPL